ArticleClinical and translational radiation oncology2026
Evaluation of submandibular gland function using quantitative
Article in Clinical and translational radiation oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrating submandibular gland transfer with proton therapy to preserve salivary function.Clinical and translational radiation oncology · 2026Article
- Comment on a submandibular gland-sparing radiotherapy study: A methodological and statistical perspective.Clinical and translational radiation oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study evaluates the efficacy of submandibular gland sparing radiotherapy in reducing salivary dysfunction using dynamic Materials and Methods: Adults with head and neck squamous cell carcinoma planned for radical radiation using volumetric modulated arc radiotherapy were recruited in the study. The salivary function was assessed using Results: Between June 2022 and January 2024, 113 patients were recruited, with scintigraphy data available for 27 patients with spared and 53 with unspared submandibular glands. At baseline, the mean Umax was 82.7 counts/second (cps) (spared) versus 81.5 cps (unspared). There was a decline at 3 months (66.5 cps vs. 72.7 cps), with significantly greater recovery by 12 months in the spared glands (81.2 cps vs. 54.8 cps; p = 0.035). SEF values at 3, 6, and 12 months respectively were 27.6 (IQR 19.6-42.1), 23.9 (IQR 17.7-31.2), and 29.9 (IQR 18.3-34.7) in spared glands compared to 2.8 (IQR -2.9-6.9), 4.4 (IQR 1.8-9.1), and 5.8 (IQR 2.6-7.6; p < 0.01 at all timepoints) in the unspared glands. At 3, 6, and 12 months, spared glands retained 78.5 %, 89.6 %, and 87.0 % function, compared to 10.5 %, 17.4 %, and 14.0 % in unspared glands (p < 0.01 at all time points). No recurrences occurred near the spared glands during the study period. Conclusion: Submandibular gland sparing is safe and significantly reduces radiation-induced salivary dysfunction. Dynamic 99mTc-pertechnetate scintigraphy is a reliable, minimally invasive method for evaluating gland function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.